<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618408</url>
  </required_header>
  <id_info>
    <org_study_id>810P301</org_study_id>
    <nct_id>NCT02618408</nct_id>
  </id_info>
  <brief_title>Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy, safety and tolerability of SPN-810
      in the treatment of impulsive aggression in subjects with Attention Deficit/Hyperactivity
      Disorder (ADHD) in conjunction with standard ADHD treatment. Approximately 291 subjects aged
      6 to 12 years with ADHD and comorbid impulsive aggression will be recruited in this study.
      The frequency of impulsive aggression behaviors will be assessed as a primary outcome.
      Additionally, the severity and improvement in impulsive aggression, and quality of life
      measures for the subject and caregiver will be assessed using validated scales.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of impulsive aggression behaviors per 7 days over a period of 7 weeks.</measure>
    <time_frame>7 weeks</time_frame>
    <description>The frequency of impulsive aggression behaviors will be assessed using an impulsive aggression diary, a newly developed and validated electronic observer reported outcome measurement tool.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>Low dose SPN-810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with low dose SPN-810</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose SPN-810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with high dose SPN-810</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be treated with a Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-810</intervention_name>
    <arm_group_label>Low dose SPN-810</arm_group_label>
    <arm_group_label>High dose SPN-810</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy male or female subjects, age 6 to 12 years at the time of screening
             with a primary diagnosis of ADHD and currently receiving monotherapy treatment with an
             optimized FDA-approved ADHD medication.

          -  Impulsive aggression will be confirmed at screening using R-MOAS and Vitiello
             Aggression Scale.

        Exclusion Criteria:

          -  Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar
             disorder, schizophrenia or related disorder, personality disorder, Tourette's
             disorder, or psychosis not otherwise specified.

          -  Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental
             disorder, obsessive compulsive disorder, post-traumatic stress disorder, or any other
             anxiety disorder as primary diagnosis.

          -  Known or suspected intelligence quotient (IQ) &lt; 70, suicidality, pregnancy, or
             substance or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefan Schwabe, MD, PhD</last_name>
    <phone>301-838-2527</phone>
    <email>sschwabe@supernus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>ProScience</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Bussel, MD</last_name>
      <phone>424-227-8127</phone>
      <email>marina.bussel@prosciencerg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chueh, MD</last_name>
      <phone>714-289-1100</phone>
      <email>dchueh@nrcresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research at Florida Clinical Research Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Zaglul, MD</last_name>
      <phone>941-747-7900</phone>
      <email>jzaglul@flcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Sarkis, MD</last_name>
      <phone>352-333-0094</phone>
      <email>ok@ehsfamily.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Marraffino, PhD</last_name>
      <phone>407-644-1165</phone>
      <email>amarraffino@flcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare of Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Harper, MD</last_name>
      <phone>407-425-5100</phone>
      <email>lharper@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Medical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Alam, MD</last_name>
      <phone>630-928-1000</phone>
      <email>myalam@americanmedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Greenbaum, MD</last_name>
      <phone>847-549-4214</phone>
      <email>mgreenbaum@capstoneclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Muphy, MD</last_name>
      <phone>913-438-8221</phone>
      <email>rory@murphyclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hugo W Moser Research Institute at Kennedy Krieger</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Findling, MD</last_name>
      <phone>443-923-9326</phone>
      <email>RFindli1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson, MD</last_name>
      <phone>585-241-9670</phone>
      <email>sda@flclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Nisonger Center Clinical Trials Program</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Arnold, MD</last_name>
      <phone>614-685-7373</phone>
      <email>L.Arnold@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peyton Lane, MD</last_name>
      <phone>405-753-4994</phone>
      <email>drpeyton@rivusinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paradigm Research Professionals</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Nixon, MD</last_name>
      <phone>405-286-2104</phone>
      <email>cnixon@researchok.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cyn3rgy Research</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials, Inc.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Lopez, MD</last_name>
      <phone>843-576-6750</phone>
      <email>Steven.Lopez2@uhsinc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Arnold, MD</last_name>
      <phone>901-843-1045</phone>
      <email>varnold@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Strategies of Memphis, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Varma, MD</last_name>
      <phone>901-685-8890</phone>
      <email>varmamd@researchmemphis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Relaro Medical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sheikh, MD</last_name>
      <phone>469-730-3282</phone>
      <email>msheikh@relaromedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bayou City Research Corporation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Brams, MD</last_name>
      <phone>832-251-7000</phone>
      <email>drmattbrams@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Miller, DO</last_name>
      <phone>210-949-0122</phone>
      <email>jmillerdo@cttexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Road Runner Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall Lucas, MD</last_name>
      <phone>832-616-2674</phone>
      <email>mlucasmd@woodlandpsych.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Anderson, DO</last_name>
      <phone>801-356-5555</phone>
      <email>drjandersen@aspclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance Research Group, LLC.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

